Maxim Group Reiterates “Buy” Rating for Brainstorm Cell Therapeutics (BCLI)
Maxim Group reiterated their buy rating on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Thursday morning. Maxim Group currently has a $9.00 price objective on the biotechnology company’s stock.
“BrainStorm announced that the Office (USPTO) granted a new US patent titled Methods of Neurotrophic Factors”. The allowed claims for the patent cover the method for generating NurOwn (MSC-NTF cells) in industrial amounts for clinical practice.”,” Maxim Group’s analyst commented.
Other analysts have also recently issued research reports about the stock. HC Wainwright set a $11.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a buy rating in a report on Monday, August 27th. ValuEngine raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating in a report on Wednesday, May 16th.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Monday, July 23rd. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). research analysts predict that Brainstorm Cell Therapeutics will post -0.49 EPS for the current fiscal year.
A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Deutsche Bank AG boosted its position in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 330.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,590 shares of the biotechnology company’s stock after acquiring an additional 75,664 shares during the quarter. Deutsche Bank AG owned 0.52% of Brainstorm Cell Therapeutics worth $386,000 at the end of the most recent quarter. 11.78% of the stock is currently owned by institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Recommended Story: Discover Your Risk Tolerance
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.